These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17952004)

  • 1. Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model.
    Pandey R; Khuller GK
    Chemotherapy; 2007; 53(6):437-41. PubMed ID: 17952004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2006 Jun; 57(6):1146-52. PubMed ID: 16597631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2006 Jun; 44(6):459-67. PubMed ID: 16784116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
    Sharma A; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
    Dutta NK; Mazumdar K; Dastidar SG; Park JH
    Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery.
    Pandey R; Ahmad Z; Sharma S; Khuller GK
    Int J Pharm; 2005 Sep; 301(1-2):268-76. PubMed ID: 16023808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral delivery of spray dried PLGA/amifostine nanoparticles.
    Pamujula S; Graves RA; Freeman T; Srinivasan V; Bostanian LA; Kishore V; Mandal TK
    J Pharm Pharmacol; 2004 Sep; 56(9):1119-25. PubMed ID: 15324480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
    Italia JL; Bhatt DK; Bhardwaj V; Tikoo K; Kumar MN
    J Control Release; 2007 Jun; 119(2):197-206. PubMed ID: 17399839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs.
    Pandey R; Sharma S; Khuller GK
    Drug Deliv; 2006; 13(4):287-94. PubMed ID: 16766470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion.
    Lu E; Franzblau S; Onyuksel H; Popescu C
    J Microencapsul; 2009 Jun; 26(4):346-54. PubMed ID: 18726818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.
    Jeong YI; Na HS; Seo DH; Kim DG; Lee HC; Jang MK; Na SK; Roh SH; Kim SI; Nah JW
    Int J Pharm; 2008 Mar; 352(1-2):317-23. PubMed ID: 18160236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles.
    Samstein RM; Perica K; Balderrama F; Look M; Fahmy TM
    Biomaterials; 2008 Feb; 29(6):703-8. PubMed ID: 18006053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.